The action of the factor is impeded by tissue factor pathway inhibitor (TFPI), which is released almost immediately after initiation of coagulation. Factor VII is vitamin K dependent; it is produced in the liver. Use of warfarin or similar anticoagulants impairs its function.
It is being increasingly used in uncontrollable hemorrhage. The first report of its use was in an Israeli soldier with uncontrollable bleeding in 1999. The rationale for its use in hemorrhage is, that it will only induce coagulation in those sites where tissue factor (TF) is also present. Still, O'Connell et al report an increased risk of deep vein thrombosis, pulmonary embolism and myocardial infarction in association with the use of rhFVIIa.
According to a 2005 study, recombinant human factor VII improves outcomes in acute intracerebral hemorrhage.
Researchers from Hadassah-Hebrew University Detail New Studies and Findings in the Area of Factor VII Deficiency
Aug 19, 2012; By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Researchers detail new data in Genetics and...